Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis

Basit Öğe Kaydı
dc.authorscopusidİrfan Çiçin / 8922379100
dc.authorwosidİrfan Çiçin / MBZ-4553-2025
dc.contributor.authorDökmetaş, Meriç
dc.contributor.authorMuğlu, Harun
dc.contributor.authorÖzcan, Erkan
dc.contributor.authorBayram Kuvvet, Buket
dc.contributor.authorHelvacı, Kaan
dc.contributor.authorKalacı, Ender
dc.contributor.authorKahraman, Seda
dc.contributor.authorAykan, Musa Barış
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorBilici, Ahmet
dc.date.accessioned2025-04-18T09:34:35Z
dc.date.available2025-04-18T09:34:35Z
dc.date.issued2025
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractBackground and Objectives: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but their use is associated with a spectrum of immune-related adverse events (irAEs), including endocrine disorders. This study aims to investigate the incidence, timing, treatment modalities, and impact of ICI-related endocrine side effects in cancer patients. Materials and Methods: This retrospective study analyzed 139 cancer patients treated with ICIs between 2016 and 2022. Data regarding endocrine irAEs, including hypothyroidism, hyperthyroidism, hypophysitis, and diabetes mellitus, were collected. The study examined the timing of irAE onset, management approaches, and the association between irAEs and treatment outcomes. Results: The most common endocrine irAE was hypothyroidism (65.5%), followed by hyperthyroidism (2.3%), hypophysitis (8.6%), and diabetes mellitus (0.7%). These disorders typically emerged within the first six months of ICI therapy. Most cases were managed conservatively or with hormone replacement therapy. Patients who developed endocrine irAEs exhibited a higher objective response rate (ORR) and clinical benefit rate (CBR) compared to those without irAEs. Conclusions: Endocrine dysfunction is a significant toxicity of ICI therapy. Early recognition, prompt diagnosis, and appropriate management are crucial to minimize their impact on patient health and quality of life. This study highlights the potential association between irAEs and improved clinical outcomes. Further research is needed to elucidate the underlying mechanisms and identify predictive biomarkers for irAE development. © 2025 by the authors.
dc.identifier.citationDökmetaş, M., Muğlu, H., Özcan, E., Bayram Kuvvet, B., Helvacı, K., Kalacı, E., ... & Bilici, A. (2025). Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis. Medicina, 61(1), 123.
dc.identifier.doi10.3390/medicina61010123
dc.identifier.issn1010660X
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85216877987
dc.identifier.scopusqualityQ1
dc.identifier.urihttp://dx.doi.org/10.3390/medicina61010123
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6822
dc.identifier.volume61
dc.identifier.wosWOS:001404273800001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.institutionauthorÇiçin, İrfan
dc.institutionauthoridİrfan Çiçin / 0000-0002-7584-3868
dc.language.isoen
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.ispartofMedicina (Lithuania)
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCancer Therapy
dc.subjectEndocrine Dysfunction
dc.subjectİmmune Checkpoint İnhibitors (ICIs)
dc.subjectİmmune-related Adverse Events (irAEs)
dc.titleEndocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Temel Tıp Bilimleri Bölümü Makale Koleksiyonu